Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GANX NASDAQ:MCRB NASDAQ:PDSB NASDAQ:QNCX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.78+1.7%$1.93$1.41▼$4.34$75.92M0.15531,560 shs412,494 shsMCRBSeres Therapeutics$7.92-1.6%$8.37$6.56▼$29.98$76.70M0.1250,005 shs21,028 shsPDSBPDS Biotechnology$1.20+3.4%$0.95$0.51▼$1.92$66.98M1.51988,910 shs1.17 million shsQNCXQuince Therapeutics$1.10+2.8%$1.17$0.79▼$45.50$17.93M1.452.09 million shs1.22 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics0.00%+1.71%-5.82%-8.25%-1.66%MCRBSeres Therapeutics0.00%+3.66%-2.10%-7.37%+2.86%PDSBPDS Biotechnology0.00%-10.45%+29.30%+85.19%-24.05%QNCXQuince Therapeutics0.00%-4.35%-19.12%-26.72%-89.32%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGANXGain Therapeutics$1.78+1.7%$1.93$1.41▼$4.34$75.92M0.15531,560 shs412,494 shsMCRBSeres Therapeutics$7.92-1.6%$8.37$6.56▼$29.98$76.70M0.1250,005 shs21,028 shsPDSBPDS Biotechnology$1.20+3.4%$0.95$0.51▼$1.92$66.98M1.51988,910 shs1.17 million shsQNCXQuince Therapeutics$1.10+2.8%$1.17$0.79▼$45.50$17.93M1.452.09 million shs1.22 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGANXGain Therapeutics0.00%+1.71%-5.82%-8.25%-1.66%MCRBSeres Therapeutics0.00%+3.66%-2.10%-7.37%+2.86%PDSBPDS Biotechnology0.00%-10.45%+29.30%+85.19%-24.05%QNCXQuince Therapeutics0.00%-4.35%-19.12%-26.72%-89.32%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGANXGain Therapeutics 2.60Moderate Buy$8.50377.53% UpsideMCRBSeres Therapeutics 2.00Hold$22.00177.78% UpsidePDSBPDS Biotechnology 2.33Hold$9.00650.00% UpsideQNCXQuince Therapeutics 1.71Reduce$65.005,809.09% UpsideCurrent Analyst Ratings BreakdownLatest QNCX, PDSB, GANX, and MCRB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)5/12/2026GANXGain Therapeutics Roth MkmSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/1/2026QNCXQuince Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/21/2026PDSBPDS Biotechnology Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/15/2026PDSBPDS Biotechnology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.004/10/2026GANXGain Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026MCRBSeres Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)3/13/2026MCRBSeres Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$22.00(Data available from 5/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGANXGain Therapeutics$50K1,518.34N/AN/A$0.33 per share5.39MCRBSeres Therapeutics$790K97.05$1.09 per share7.29$2.74 per share2.89PDSBPDS BiotechnologyN/AN/AN/AN/A$0.07 per shareN/AQNCXQuince TherapeuticsN/AN/AN/AN/A$0.96 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGANXGain Therapeutics-$20.16M-$0.58N/AN/AN/AN/A-201.44%-136.24%8/11/2026 (Estimated)MCRBSeres Therapeutics$5.70M-$5.17N/AN/AN/AN/A-130.29%-35.35%8/5/2026 (Estimated)PDSBPDS Biotechnology-$34.50M-$0.67N/AN/AN/AN/A-346.02%-102.36%8/12/2026 (Estimated)QNCXQuince Therapeutics-$83.98M-$10.62N/AN/AN/AN/A-372.88%-67.99%8/11/2026 (Estimated)Latest QNCX, PDSB, GANX, and MCRB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026PDSBPDS Biotechnology-$0.15-$0.13+$0.02-$0.13N/AN/A5/11/2026Q1 2026GANXGain Therapeutics-$0.13-$0.13N/A-$0.13$0.03 millionN/A5/11/2026Q1 2026QNCXQuince Therapeutics-$1.30-$0.59+$0.71$2.88N/AN/A5/5/2026Q1 2026MCRBSeres Therapeutics-$1.88-$2.08-$0.20-$2.08$0.36 million$0.36 million3/30/2026Q4 2025PDSBPDS Biotechnology-$0.20-$0.14+$0.06-$0.14N/AN/A3/26/2026Q4 2025GANXGain Therapeutics-$0.14-$0.11+$0.03-$0.11$0.03 millionN/A3/12/2026Status updateMCRBSeres Therapeutics-$2.39-$1.89+$0.50-$1.76N/A$0.44 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthGANXGain TherapeuticsN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/APDSBPDS BiotechnologyN/AN/AN/AN/AN/AQNCXQuince TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGANXGain Therapeutics0.024.694.69MCRBSeres TherapeuticsN/A1.651.65PDSBPDS Biotechnology2.732.262.26QNCXQuince TherapeuticsN/A2.922.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGANXGain Therapeutics11.97%MCRBSeres Therapeutics59.34%PDSBPDS Biotechnology26.84%QNCXQuince Therapeutics30.75%Insider OwnershipCompanyInsider OwnershipGANXGain Therapeutics4.15%MCRBSeres Therapeutics4.70%PDSBPDS Biotechnology9.20%QNCXQuince Therapeutics20.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGANXGain Therapeutics2042.65 million40.88 millionOptionableMCRBSeres Therapeutics3309.68 million9.23 millionOptionablePDSBPDS Biotechnology2055.82 million50.68 millionOptionableQNCXQuince Therapeutics6016.30 million12.99 millionOptionableQNCX, PDSB, GANX, and MCRB HeadlinesRecent News About These CompaniesQuince Therapeutics Regains Nasdaq Compliance, Avoids Delisting Risk3 hours ago | theglobeandmail.comQuince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks TranscriptMay 18, 2026 | seekingalpha.comUPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDMay 18, 2026 | globenewswire.comQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILDMay 18, 2026 | globenewswire.comQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary PipelineMay 18, 2026 | globenewswire.comQuince Therapeutics, Inc. (NASDAQ:QNCX) Receives Average Rating of "Reduce" from BrokeragesMay 17, 2026 | americanbankingnews.comQuince Therapeutics (NASDAQ:QNCX) Upgraded at Wall Street ZenMay 17, 2026 | americanbankingnews.comQuince Therapeutics (QNCX) price target increased by 100.00% to 81.60May 15, 2026 | msn.comQuince Therapeutics (QNCX) price target increased by 900.00% to 40.80April 28, 2026 | msn.comQuince Therapeutics Delays Annual 10-K FilingApril 27, 2026 | theglobeandmail.comQuince Therapeutics settles $16.4M debt with $5.5M paymentMarch 30, 2026 | msn.comWhy did QNCX stock surge 40% in pre-market today?March 30, 2026 | msn.comQuince Therapeutics Settles Approximately $16.4 Million of DebtMarch 30, 2026 | businesswire.comBankruptcy threat looms as Quince runs out of optionsFebruary 13, 2026 | pharmaphorum.comPQuince Therapeutics stock plummets after revealing strategic alternativesFebruary 13, 2026 | au.investing.comQuince Therapeutics (QNCX) Stock Erupts 300% as Buyout Rumors EmergeFebruary 11, 2026 | blockonomi.comQuince Therapeutics stock soars after engaging LifeSci Capital as advisorFebruary 10, 2026 | au.investing.comWhy is QNCX stock up 60% pre-market after a near-total wipeout?February 10, 2026 | msn.comQuince Therapeutics Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic AlternativesFebruary 9, 2026 | businesswire.comPolaryx Therapeutics, Inc. Strengthens Board of Directors with New Appointments as Company Advances to Phase 2 TrialFebruary 5, 2026 | quiverquant.comQNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQNCX, PDSB, GANX, and MCRB Company DescriptionsGain Therapeutics NASDAQ:GANX$1.78 +0.03 (+1.71%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.78 -0.01 (-0.28%) As of 05/22/2026 07:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Seres Therapeutics NASDAQ:MCRB$7.92 -0.13 (-1.61%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$7.93 +0.01 (+0.18%) As of 05/22/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.PDS Biotechnology NASDAQ:PDSB$1.20 +0.04 (+3.45%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.24 +0.04 (+2.92%) As of 05/22/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.Quince Therapeutics NASDAQ:QNCX$1.10 +0.03 (+2.80%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.11 +0.01 (+0.91%) As of 05/22/2026 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Palantir and Dell Build an AI OS for the Paranoid Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
